Page 2 - Dave Moeller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MedCity News
Medtronic CEO expects to submit renal denervation data to FDA this year, overcoming previous failures
Medtronic suffered a shocking setback back in 2014 when its Symplicity 3 pivotal trial failed to meet its primary endpoint of reducing blood pressure meaningfully. Now it is gearing up to present new data to the FDA.
Shares1
If Medtronic is successful in bringing its renal denervation product to the U.S. market to treat drug-resistant hypertension as its current CEO Geoff Martha expects to, the entire saga could be summarized with Chumbawamba’s famous song from the late 1990s:
      I get knocked down, but I get up again ....

Symplicity Spyral Denervation , Dave Moeller , Medtronic Symplicity , Geoff Martha , Healthcare Conference , Symplictity Denervation System , Renal Denervation , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Motion Sensors , Healthcare It , Foodborne Pathogens , Diagnostics Company , Diagnostic Platforms , Minimally Invasive Surgery , Laser Surgery , Health And Wellness , Employee Wellness Programs ,